心臓安全性サービス市場 : 2027 年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2022年8月

心臓安全性サービス市場 : タイプ (スタンドアロン、統合)、サービス (ECG/ホルター、血圧、心臓画像、エンドツーエンド QT 研究)、エンドユーザー (製薬、バイオ製​​薬、CRO)、地域別 – 2027 年までの世界予測
Cardiac Safety Services Market by Type (Standalone, Integrated), Services (ECG/Holter measurement, Blood Pressure measurement, Cardiac Imaging, Thorough QT Studies), End User (Pharmaceutical, Biopharma, CROs), Region – Global Forecast to 2027

ページ数 128
図表数 141
種別 英文調査報告書
価格 こちらをご覧ください

レポート目次    お問合せ・ご注文    価格・納期について

無料サンプル

The cardiac safety services market is projected to reach USD 1.0 Billion by 2027 from USD 0.6 Billion in 2022, at a CAGR of 11.2% during the forecast period. The increasing expenditure by pharmaceutical companies, alongside rising government spending is leading has driven the pace of R&D activity in this industry to develop new drugs. This will contribute to the need for numerous preclinical and clinical services during drug development, including cardiac safety evaluation.

心臓安全性サービス市場 : タイプ (スタンドアロン、統合)、サービス (ECG/ホルター、血圧、心臓画像、エンドツーエンド QT 研究)、エンドユーザー (製薬、バイオ製​​薬、CRO)、地域別 - 2027 年までの世界予測
“The Blood Pressure Measurement segment accounted for the second largest share of the type of services market in 2021”
Blood pressure monitoring is an essential part of cardiac safety services. Increasing R&D activities and stringent clinical trial regulations make blood pressure measurement a critical parameter from both an efficacy and a safety endpoint. This factor is expected to drive the growth of this market segment.
“The contract research organizations (CROs) accounted for the second largest share of the end user market in 2021”
CROs provide specialized services to pharmaceutical & biopharmaceutical companies at a low cost. As a result, many pharmaceutical & biopharmaceutical companies are outsourcing their drug discovery services to CROs. As cardiac safety services are critical in drug development processes, their adoption is expected to increase with an increase in outsourcing
Laboratory Corporation of America Holdings (US), Koninklijke Philips N.V. (Netherlands), Clario (US), Banook Group (France), IQVIA (US), Biotrial (France), Certara (US), Celerion (US), Medpace (US), Ncardia (Netherlands), Richmond Pharmacology (UK), PhysioStim (France), Shanghai Medicilon (China), Pharmaceutical Product Development (US), and SGS (Switzerland) are some of the major players operating in the market.

“Europe: The second largest share in the cardiac safety services market”
The European market includes Germany, the UK, France, Italy, Spain, and the RoE. It accounted for the second largest market share of the cardiac safety services market. Important considerations include demographic changes, such as the growing incidence of chronic diseases is expected to drive the market growth in the region

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side – 20%
• By Designation: Managers- 45%, CXOs and Director level – 30%, and Executives – 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Laboratory Corporation of America Holdings (US)
• Koninklijke Philips N.V. (Netherlands)
• Clario (US)
• Banook Group (France)
• IQVIA (US)
• Biotrial (France)
• Certara (US)
• Celerion (US)
• Medpace (US)
• Ncardia (Netherlands)
• Richmond Pharmacology (UK)
• PhysioStim (France)
• Shanghai Medicilon (China)
• Pharmaceutical Product Development (US)
• SGS (Switzerland)

心臓安全性サービス市場 : タイプ (スタンドアロン、統合)、サービス (ECG/ホルター、血圧、心臓画像、エンドツーエンド QT 研究)、エンドユーザー (製薬、バイオ製​​薬、CRO)、地域別 - 2027 年までの世界予測
Research Coverage:
This report provides a detailed picture of the cardiac safety services market. It aims at estimating the size and future growth potential of the market across different segments such as the type, type of service, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cardiac safety services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, challenges, trends, and opportunities.


目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. – 20)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
FIGURE 1 CARDIAC SAFETY SERVICES MARKET
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 LIMITATIONS
1.7 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. – 23)

2.1 RESEARCH DATA
FIGURE 2 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key data from primary sources
2.1.2.2 Key industry insights
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
FIGURE 4 BOTTOM-UP APPROACH
2.2.2 TOP-DOWN APPROACH
FIGURE 5 TOP-DOWN APPROACH
2.2.3 GROWTH FORECAST
2.3 DATA TRIANGULATION
FIGURE 6 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. – 31)
FIGURE 7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 8 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 9 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF CARDIAC SAFETY SERVICES MARKET

4 PREMIUM INSIGHTS (Page No. – 34)
4.1 CARDIAC SAFETY SERVICES MARKET OVERVIEW
FIGURE 11 INCREASING NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH
4.2 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE AND COUNTRY (2021)
FIGURE 12 INTEGRATED SERVICES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2021
4.3 CARDIAC SAFETY SERVICES MARKET SHARE, BY TYPE OF SERVICE, 2022 VS. 2027
FIGURE 13 ECG/HOLTER MEASUREMENT SERVICES SEGMENT TO DOMINATE MARKET IN 2027
4.4 CARDIAC SAFETY SERVICES MARKET SHARE, BY END USER, 2022
FIGURE 14 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022
4.5 CARDIAC SAFETY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 15 EUROPEAN COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

5 MARKET OVERVIEW (Page No. – 38)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 16 CARDIAC SAFETY SERVICES MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Growing R&D expenditure in pharmaceutical & biopharmaceutical industry
FIGURE 17 GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026
5.2.1.2 Increased outsourcing of R&D activities
FIGURE 18 ACTIVE PHARMACEUTICAL DRUG PIPELINE, JANUARY 2011 TO JANUARY 2021
5.2.1.3 Increasing number of clinical trials
FIGURE 19 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000–2021)
5.2.2 OPPORTUNITIES
5.2.2.1 Introduction of new technologies and methods
5.2.2.2 Growth in biosimilars and biologics markets
5.2.3 CHALLENGES
5.2.3.1 High cost of cardiac safety evaluation

6 CARDIAC SAFETY SERVICES MARKET, BY TYPE (Page No. – 43)
6.1 INTRODUCTION
TABLE 1 CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
6.2 INTEGRATED SERVICES
6.2.1 INTEGRATED SERVICES TO DOMINATE CARDIAC SAFETY SERVICES MARKET
TABLE 2 INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 3 NORTH AMERICA: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 4 EUROPE: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 5 ASIA PACIFIC: INTEGRATED CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
6.3 STANDALONE SERVICES
6.3.1 STANDALONE SERVICES SEGMENT WITNESSING GROWTH DUE TO COST-EFFECTIVENESS
TABLE 6 STANDALONE CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 7 NORTH AMERICA: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 8 EUROPE: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 9 ASIA PACIFIC: STANDALONE CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

7 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE (Page No. – 49)
7.1 INTRODUCTION
TABLE 10 CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
7.2 ECG/HOLTER MEASUREMENT SERVICES
7.2.1 ECG/HOLTER MEASUREMENT SERVICES SUPPORT R&D IN NOVEL METHODS FOR CLINICAL TRIALS AND DRUG DISCOVERY
TABLE 11 ECG/HOLTER MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 12 NORTH AMERICA: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 13 EUROPE: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 14 ASIA PACIFIC: ECG/HOLTER MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.3 BLOOD PRESSURE MEASUREMENT SERVICES
7.3.1 INCREASING R&D ACTIVITIES TO DRIVE MARKET GROWTH
TABLE 15 BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 16 NORTH AMERICA: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 17 EUROPE: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 18 ASIA PACIFIC: BLOOD PRESSURE MEASUREMENT SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.4 CARDIOVASCULAR IMAGING SERVICES
7.4.1 CARDIOVASCULAR IMAGING SERVICES HELP IN DRUG EVALUATION
TABLE 19 CARDIOVASCULAR IMAGING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 20 NORTH AMERICA: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 21 EUROPE: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 22 ASIA PACIFIC: CARDIOVASCULAR IMAGING SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.5 THOROUGH QT STUDIES
7.5.1 NEED TO MEET STRINGENT REGULATORY REQUIREMENTS TO DRIVE DEMAND FOR THOROUGH QT STUDIES
TABLE 23 THOROUGH QT STUDIES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 NORTH AMERICA: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 25 EUROPE: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 26 ASIA PACIFIC: THOROUGH QT STUDIES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
7.6 OTHER SERVICES
TABLE 27 OTHER CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 28 NORTH AMERICA: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 29 EUROPE: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 30 ASIA PACIFIC: OTHER CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)

8 CARDIAC SAFETY SERVICES MARKET, BY END USER (Page No. – 60)
8.1 INTRODUCTION
TABLE 31 CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
8.2.1 INCREASING R&D BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE DEMAND FOR CARDIAC SAFETY SERVICES
TABLE 32 CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2020–2027 (USD MILLION)
TABLE 33 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 34 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 35 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION)
8.3 CONTRACT RESEARCH ORGANIZATIONS
8.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY PROCESSES TO SUPPORT SEGMENT GROWTH
TABLE 36 CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020–2027 (USD MILLION)
TABLE 37 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 38 EUROPE: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 39 ASIA PACIFIC: CARDIAC SAFETY SERVICES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020–2027 (USD MILLION)

9 CARDIAC SAFETY SERVICES MARKET, BY REGION (Page No. – 66)
9.1 INTRODUCTION
TABLE 40 CARDIAC SAFETY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
9.2 NORTH AMERICA
FIGURE 20 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET SNAPSHOT
TABLE 41 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 42 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 43 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 44 NORTH AMERICA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.1 US
9.2.1.1 US dominates global cardiac safety services market
TABLE 45 US: TOTAL NUMBER OF CLINICAL TRIALS (2019)
TABLE 46 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 47 US: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 48 US: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2.2 CANADA
9.2.2.1 Canada has high-quality clinical trial infrastructure and expertise
TABLE 49 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 50 CANADA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 51 CANADA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3 EUROPE
FIGURE 21 EUROPE: CARDIAC SAFETY SERVICES MARKET SNAPSHOT
TABLE 52 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 53 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 54 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 55 EUROPE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.1 GERMANY
9.3.1.1 Availability of skilled staff and flexible labor laws have made Germany a popular EU hub for clinical trials
TABLE 56 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 57 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 58 GERMANY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.2 UK
9.3.2.1 Steady growth of pharmaceutical R&D expenditure indicates favorable prospects for cardiac safety services
TABLE 59 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 60 UK: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 61 UK: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.3 FRANCE
9.3.3.1 High clinical trial activity for cancer therapies to drive market growth
TABLE 62 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 63 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 FRANCE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.4 ITALY
9.3.4.1 Strong pharma industry and availability of funding for drug development fuel market growth
TABLE 65 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
TABLE 66 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 67 ITALY: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 68 ITALY: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.5 SPAIN
9.3.5.1 Growing investment in pharmaceutical R&D and a favorable climate for approvals boost market growth
TABLE 69 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 70 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 71 SPAIN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.3.6 REST OF EUROPE
TABLE 72 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 73 ROE: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 74 ROE: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4 ASIA PACIFIC
TABLE 75 APAC: CARDIAC SAFETY SERVICES MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 76 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 77 APAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 78 APAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.1 CHINA
9.4.1.1 China dominates APAC market for cardiac safety services
TABLE 79 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 80 CHINA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 81 CHINA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.2 JAPAN
9.4.2.1 Strong IP rights and supportive policies have strengthened R&D sector in Japan
TABLE 82 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 83 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 JAPAN: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.3 INDIA
9.4.3.1 Lack of language barriers and availability of trained resources make India an attractive destination for clinical trials
TABLE 85 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 86 INDIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 87 INDIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.4 AUSTRALIA
9.4.4.1 Favorable R&D tax incentives and cash rebates have driven clinical trial activity in Australia
TABLE 88 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 89 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 90 AUSTRALIA: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.4.5 REST OF ASIA PACIFIC
TABLE 91 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 92 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 93 ROAPAC: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)
9.5 REST OF THE WORLD
TABLE 94 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE OF SERVICE, 2020–2027 (USD MILLION)
TABLE 95 ROW: CARDIAC SAFETY SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 ROW: CARDIAC SAFETY SERVICES MARKET, BY END USER, 2020–2027 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. – 97)
10.1 OVERVIEW
FIGURE 22 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM 2019–2022
10.2 MARKET PLAYER RANKING
TABLE 97 GLOBAL CARDIAC SAFETY SERVICES MARKET PLAYER RANKING, 2021
10.3 COMPETITIVE LEADERSHIP MAPPING
10.3.1 VISIONARY LEADERS
10.3.2 DYNAMIC DIFFERENTIATORS
10.3.3 INNOVATORS
10.3.4 EMERGING COMPANIES
FIGURE 23 CARDIAC SAFETY SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING
10.4 COMPETITIVE SITUATION AND TRENDS
10.4.1 ACQUISITIONS
TABLE 98 ACQUISITIONS, 2019–2022
10.4.2 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS
TABLE 99 PARTNERSHIPS, ALLIANCES, AND AGREEMENTS, 2019–2022
10.4.3 EXPANSIONS
TABLE 100 EXPANSIONS, 2019–2022
10.4.4 OTHER STRATEGIES
TABLE 101 OTHER STRATEGIES, 2019–2022

11 COMPANY PROFILES (Page No. – 103)
(Business overview, Products offered, Recent Developments, MNM view)*
11.1 KEY PLAYERS
11.1.1 LABORATORY CORPORATION OF AMERICA HOLDINGS
TABLE 102 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW
FIGURE 24 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT
11.1.2 KONINKLIJKE PHILIPS
TABLE 103 KONINKLIJKE PHILIPS: BUSINESS OVERVIEW
FIGURE 25 KONINKLIJKE PHILIPS: COMPANY SNAPSHOT
11.1.3 CLARIO
TABLE 104 CLARIO: BUSINESS OVERVIEW
11.1.4 BANOOK GROUP
TABLE 105 BANOOK GROUP: BUSINESS OVERVIEW
11.1.5 IQVIA
TABLE 106 IQVIA: BUSINESS OVERVIEW
FIGURE 26 IQVIA: COMPANY SNAPSHOT
11.1.6 BIOTRIAL
TABLE 107 BIOTRIAL: BUSINESS OVERVIEW
11.1.7 CERTARA
TABLE 108 CERTARA: BUSINESS OVERVIEW
FIGURE 27 CERTARA: COMPANY SNAPSHOT
11.1.8 CELERION
TABLE 109 CELERION: BUSINESS OVERVIEW
11.1.9 MEDPACE
TABLE 110 MEDPACE: BUSINESS OVERVIEW
FIGURE 28 MEDPACE: COMPANY SNAPSHOT
11.1.10 NCARDIA
TABLE 111 NCARDIA: BUSINESS OVERVIEW
11.1.11 RICHMOND PHARMACOLOGY
TABLE 112 RICHMOND PHARMACOLOGY: BUSINESS OVERVIEW
11.1.12 PHYSIOSTIM
TABLE 113 PHYSIOSTIM: BUSINESS OVERVIEW
11.2 OTHER PLAYERS
11.2.1 SHANGHAI MEDICILON
11.2.2 PHARMACEUTICAL PRODUCT DEVELOPMENT LLC.
11.2.3 SGS S.A.

*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

12 APPENDIX (Page No. – 126)
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS


    お問合せフォーム

    • レポートのタイトルは自動で入ります。
    • *のある項目は必須項目です。

    お名前*

    会社名*

    部署名

    メールアドレス*

    電話番号

    当ウェブサイトを知った経緯を教えてください。

    お問合せ内容

    株式会社SEMABIZ・ChosaReport.com プライバシーポリシー

    Eメールでのお問合せもお受けしております。
    下記アドレスへ“(at)”を“@”に変えてお送りください。通常1営業日以内にご返信いたします。
    crinquiry(at)chosareport.com